Digitalization And M&A Will Expand Pharma And Consumer Markets

Published
25 Nov 24
Updated
20 Aug 25
AnalystConsensusTarget's Fair Value
€145.43
34.8% undervalued intrinsic discount
20 Aug
€94.82
Loading
1Y
-33.4%
7D
2.4%

Author's Valuation

€145.4

34.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 9.49%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 1.73%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 0.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 0.97%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 5.28%

AnalystConsensusTarget has increased future PE multiple from 30.6x to 34.7x.